17,261 trials
Renal Cell Carcinoma · Neoplasm Metastases
Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…
Asthma
Primary: Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period — 215.9…
Tobacco Use Disorder
Primary: Median Urinary PGE-M Levels (Pre and Post Treatment) — 12.8; 13.4; 10.5; 3.9 ng/mg creatinine
Melanoma
Primary: Activity of Vemurafenib in Untreated Brain Metastases
Alzheimer Disease
Primary: Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog) — -3.2; -3.5 units on a scale — p=>0.1
Late Complication From Skin Graft · Infection of Skin Donor Site · Impaired Wound Healing
Primary: Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment — 12 Days
Asthma
Primary: Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1 — 90.97; 91.32; 87.28…
Precancerous Condition
Primary: Change in Histopathology Score of Sun Damaged Skin by Treatment Group — 0.4; -0.1; 0.1 units on a scale — p=0.10
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder(Not in Manic Phase)
Primary: Positive and Negative Syndrome Scale (PANSS) — 18.24; 19.18; 18.18; 14.11 units on a scale
Acute Myeloid Leukemia
Primary: Overall Response Rate (ORR) — 48 percentage of participants
Gastrin-Producing Neuroendocrine Tumor · Lung Carcinoid Tumor · Metastatic Digestive System Neuroendocrine Tumor G1
Primary: Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 6; 14; 21 participants
Prostate Cancer
Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…
Solid Tumors and Advanced Endometrial Cancer · Endometrial Cancer · Second-line Treatment
Primary: Progression Free Survival (PFS) Rate — 31.8; 29.0 Percentage of participants
Childhood Alveolar Soft Part Sarcoma · Childhood Angiosarcoma · Childhood Epithelioid Sarcoma
Primary: Objective Response Rate (PR or CR) by Response Evaluation Criteria in Solid Tumors (RECIST). — 10; 11; 11; 11 participants
Fabry Disease
Primary: Estimated Glomerular Filtration Rate (eGFR) — -0.66; -0.32 ml/min/month — p=0.01